<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults - Derry, S - 2017 | Cochrane Library</title> <meta content="Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults - Derry, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults - Derry, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012332.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults" name="citation_title"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Martin Mücke" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Thomas Rudolf Tölle" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="andrew.moore@omkltd.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012332.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti‐Inflammatory Agents, Non‐Steroidal [*administration &amp; dosage, adverse effects]; Fibromyalgia [*drug therapy]; Pain Measurement [methods]; Randomized Controlled Trials as Topic; Withholding Treatment [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012332.pub2&amp;doi=10.1002/14651858.CD012332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012332\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012332\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012332.pub2",title:"Oral nonsteroidal anti\\u2010inflammatory drugs for fibromyalgia in adults",firstPublishedDate:"Mar 27, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012332.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012332.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012332.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012332.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012332.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012332.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012332.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012332.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012332.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012332.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3805 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012332.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/appendices#CD012332-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/table_n/CD012332StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/table_n/CD012332StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0002">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0003">Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0004">Winfried Häuser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0005">Martin Mücke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0006">Thomas Rudolf Tölle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0007">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information#CD012332-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information/en#CD012332-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012332.pub2">https://doi.org/10.1002/14651858.CD012332.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012332-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012332-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012332-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012332-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012332-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012332-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012332-abs-0001" lang="en"> <section id="CD012332-sec-0001"> <h3 class="title" id="CD012332-sec-0001">Background</h3> <p>Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used in the treatment of pain in fibromyalgia, despite being considered not to be effective. </p> </section> <section id="CD012332-sec-0002"> <h3 class="title" id="CD012332-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy, tolerability (drop‐out due to adverse events), and safety (serious adverse events) of oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults. </p> </section> <section id="CD012332-sec-0003"> <h3 class="title" id="CD012332-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, and Embase for randomised controlled trials from inception to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trial registries. </p> </section> <section id="CD012332-sec-0004"> <h3 class="title" id="CD012332-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind trials of two weeks' duration or longer, comparing any oral NSAID with placebo or another active treatment for relief of pain in fibromyalgia, with subjective pain assessment by the participant. </p> </section> <section id="CD012332-sec-0005"> <h3 class="title" id="CD012332-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)) or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC), serious adverse events, and withdrawals due to adverse events; secondary outcomes were adverse events, withdrawals due to lack of efficacy, and outcomes relating to sleep, fatigue, and quality of life. Where pooled analysis was possible, we used dichotomous data to calculate risk difference (RD) and number needed to treat for an additional beneficial outcome (NNT), using standard methods. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD012332-sec-0006"> <h3 class="title" id="CD012332-sec-0006">Main results</h3> <p>Our searches identified six randomised, double‐blind studies involving 292 participants in suitably characterised fibromyalgia. The mean age of participants was between 39 and 50 years, and 89% to 100% were women. The initial pain intensity was around 7/10 on a 0 to 10 pain scale, indicating severe pain. NSAIDs tested were etoricoxib 90 mg daily, ibuprofen 2400 mg daily, naproxen 1000 mg daily, and tenoxicam 20 mg daily; 146 participants received NSAID and 146 placebo. The duration of treatment in the double‐blind phase varied between three and eight weeks. </p> <p>Not all studies reported all the outcomes of interest. Analyses consistently showed no significant difference between NSAID and placebo: substantial benefit (at least 50% pain intensity reduction) (risk difference (RD) ‐0.07 (95% confidence interval (CI) ‐0.18 to 0.04) 2 studies, 146 participants; moderate benefit (at least 30% pain intensity reduction) (RD ‐0.04 (95% CI ‐0.16 to 0.08) 3 studies, 192 participants; withdrawals due to adverse events (RD 0.04 (95% CI ‐0.02 to 0.09) 4 studies, 230 participants; participants experiencing any adverse event (RD 0.08 (95% CI ‐0.03 to 0.19) 4 studies, 230 participants; all‐cause withdrawals (RD 0.03 (95% CI ‐0.07 to 0.14) 3 studies, 192 participants. There were no serious adverse events or deaths. Although most studies had some measures of health‐related quality of life, fibromyalgia impact, or other outcomes, none reported the outcomes beyond saying that there was no or little difference between the treatment groups. </p> <p>We downgraded evidence on all outcomes to very low quality, meaning that this research does not provide a reliable indication of the likely effect. The likelihood that the effect could be substantially different is very high. This is based on the small numbers of studies, participants, and events, as well as other deficiencies of reporting study quality allowing possible risks of bias. </p> </section> <section id="CD012332-sec-0007"> <h3 class="title" id="CD012332-sec-0007">Authors' conclusions</h3> <p>There is only a modest amount of very low‐quality evidence about the use of NSAIDs in fibromyalgia, and that comes from small, largely inadequate studies with potential risk of bias. That bias would normally be to increase the apparent benefits of NSAIDs, but no such benefits were seen. Consequently, NSAIDs cannot be regarded as useful for treating fibromyalgia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012332-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012332-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012332-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012332-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012332-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012332-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012332-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012332-abs-0003" lang="en"> <h3>Oral NSAIDs for treating fibromyalgia pain in adults</h3> <p><b>Bottom line</b> </p> <p>We found very low‐quality evidence that oral non‐steroidal anti‐inflammatory drugs (NSAIDs) have no effect on pain or other symptoms in people with moderate or severe pain from fibromyalgia. Ibuprofen and diclofenac are common NSAIDs. </p> <p><b>Background</b> </p> <p>Fibromyalgia is characterised by persistent, widespread pain, sleep problems, and fatigue. NSAIDs are drugs with analgesic (pain‐killing), antipyretic (fever‐reducing) effects, and also with anti‐inflammatory effects at higher doses. NSAIDs are frequently used to treat rheumatic diseases. </p> <p>Our definition of a good result was someone who had a high level of pain relief and was able to keep taking the medicine without side effects that made them want to stop. </p> <p><b>Study characteristics</b> </p> <p>We searched for clinical trials in which NSAIDs were used to treat symptoms of fibromyalgia in adults. The latest search was in January 2017. Six studies satisfied the inclusion criteria, randomising 292 participants to treatment with NSAID or placebo. NSAIDs tested were etoricoxib 90 mg daily, ibuprofen 2400 mg daily, naproxen 1000 mg daily, and tenoxicam 20 mg daily; 146 participants received NSAID and 146 placebo. Study duration was between three and eight weeks. Not all studies reported the outcomes of interest. </p> <p><b>Key results</b> </p> <p>We found no difference between NSAID or placebo for a range of outcomes. Pain reduction by half or better was experienced by 1 in 10 with NSAID and 2 in 10 with placebo. Pain reduction by a third or better was experienced by about 2 in 10 with both NSAID and placebo. Side effects were experienced by 3 in 10 with NSAID and 2 in 10 with placebo. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence was of very low quality. This means that the research does not provide a reliable indication of the likely effect. The chance that the real effect of NSAIDs could be substantially different is very high. Small studies like those in this review tend to overestimate results of treatment compared to the effects found in larger, better studies. The very low‐quality evidence and the lack of any obvious benefit mean that NSAIDs cannot be regarded as useful for the management of fibromyalgia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012332-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012332-sec-0088"></div> <h3 class="title" id="CD012332-sec-0089">Implications for practice</h3> <section id="CD012332-sec-0089"> <section id="CD012332-sec-0090"> <h5 class="title">For people with pain in fibromyalgia</h5> <p>There is no evidence to support the suggestion that nonsteroidal anti‐inflammatory drugs (NSAIDs) have any efficacy in relieving pain or other symptoms in people with fibromyalgia. There is limited evidence to indicate that NSAIDs are without any effect. Some people with fibromyalgia may have other painful conditions such inflammatory rheumatic diseases or osteoarthritis for which an NSAID can be useful. </p> </section> <section id="CD012332-sec-0091"> <h5 class="title">For clinicians</h5> <p>There is no evidence to support the suggestion that NSAIDs have any efficacy in relieving pain in people with fibromyalgia. There is limited evidence to indicate that NSAIDs are without any effect. Any biases in the small studies we identified would be expected to work to increase estimates of efficacy, and the fact that no efficacy was found strengthens the conclusions that NSAIDs are ineffective. Some people with fibromyalgia may have other painful conditions for which an NSAID is indicated. </p> </section> <section id="CD012332-sec-0092"> <h5 class="title">For policy makers</h5> <p>There is no evidence to support the suggestion that NSAIDs have any efficacy in relieving pain in people with fibromyalgia. There is limited evidence to indicate that NSAIDs are without any effect. Any biases in the small studies we have would be expected to work to increase estimates of efficacy, and the fact that no efficacy was found strengthens the conclusions that NSAIDs are ineffective. Some people with fibromyalgia may have other painful conditions for which an NSAID can be useful, such as concomitant inflammatory rheumatic diseases or osteoarthritis. </p> </section> <section id="CD012332-sec-0093"> <h5 class="title">For funders</h5> <p>There is no evidence to support the suggestion that NSAIDs have any efficacy in relieving pain in people with fibromyalgia. There is limited evidence to indicate that NSAIDs are without any effect. In the absence of any additional supporting evidence, NSAIDs should probably not be recommended, except at the discretion of a pain specialist with particular expertise in fibromyalgia. </p> </section> </section> <h3 class="title" id="CD012332-sec-0094">Implications for research</h3> <section id="CD012332-sec-0094"> <section id="CD012332-sec-0095"> <h5 class="title">General</h5> <p>Although the amount of clinical trial evidence in this review is limited, the absence of any signal for efficacy calls into question the ethics and value of any new study for people with fibromyalgia without concomitant inflammatory rheumatic disease osteoarthritis. The design of studies in fibromyalgia, and the outcomes, are well understood; but as any NSAID effect is likely to be small, an enriched‐enrolment randomised‐withdrawal (EERW) design might provide the highest sensitivity to detect a signal (<a href="./references#CD012332-bbs2-0082" title="MooreRA , WiffenPJ , EcclestonC , DerryS , BaronR , BellRF , et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain2015;156(8):1382‐95. [DOI: 10.1097/j.pain.0000000000000088] ">Moore 2015</a>). </p> </section> <section id="CD012332-sec-0096"> <h5 class="title">Design</h5> <p>The design of trials is generally adequate, but reporting of clinically relevant outcomes using appropriate imputation for withdrawal would improve the relevance of the findings for clinical practice. The use of EERW designs for comparison with classic trial designs indicates that good quality EERW designs of long duration may be appropriate for fibromyalgia. </p> </section> <section id="CD012332-sec-0097"> <h5 class="title">Measurement (endpoints)</h5> <p>Assessment of fibromyalgia symptoms should be based on dichotomous participant‐reported outcomes of proven clinical utility; that usually means pain intensity reduction of at least 50% (or possibly 30%) without withdrawal from treatment, typically at 12 weeks after dosing stabilisation. The end point most usefully used in EERW trials, of maintenance of therapeutic response without withdrawal, might be used as a primary outcome in future trials with that design. </p> </section> <section id="CD012332-sec-0098"> <h5 class="title">Comparison between active treatments</h5> <p>Studies involving other treatments including non‐pharmacological interventions may be valuable in the context of fibromyalgia. A multi‐component approach reflects current practice. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012332-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012332-sec-0029"></div> <div class="table" id="CD012332-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAID compared with placebo for fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAID compared with placebo for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with fibromyalgia</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: any NSAID</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> <p><b>(at trial end)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> NSAID</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substantial pain relief:</p> <p>at least 50% reduction in pain, or</p> <p>PGIC much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.07 (95% CI ‐0.18 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>146 participants</p> <p>21 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain relief:</p> <p>at least 30% reduction in pain, or</p> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.04 (95% CI ‐0.16 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>192 participants</p> <p>46 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event withdrawal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.04 (95% CI ‐0.02 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>230 participants</p> <p>8 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.08 (95% CI ‐0.03 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>230 participants</p> <p>61 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause withdrawal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.03 (‐0.07 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>192 participants</p> <p>41 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012332-bbs2-0026" title="EffectivePractice , Organisation of Care(EPOC) . EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services2015; Vol. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>a</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is very high. </p> <p><sup>a</sup>Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012332-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012332-sec-0030"></div> <p>This review is based on a template for reviews of drugs used to relieve fibromyalgia. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012332-bbs2-0068" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./appendices#CD012332-sec-0102">Appendix 1</a>) and fibromyalgia (<a href="./references#CD012332-bbs2-0062" title="MeaseP , ArnoldLM , ChoyEH , ClauwDJ , CroffordLJ , GlassJ , et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. Journal of Rheumatology2009;36(10):2318‐29. [DOI: 10.3899/jrheum.090367] ">Mease 2009</a>). </p> <section id="CD012332-sec-0031"> <h3 class="title" id="CD012332-sec-0031">Description of the condition</h3> <p>Fibromyalgia symptoms can be assessed by self report of the person using the fibromyalgia criteria and severity scales for clinical and epidemiological studies, a modification of the American College of Rheumatology (ACR) Preliminary Diagnostic Criteria for Fibromyalgia (so‐called Fibromyalgia Symptom Questionnaire) (<a href="./references#CD012332-bbs2-0108" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology2011;38:1113‐22. [DOI: 10.3899/jrheum.100594] ">Wolfe 2011</a>). Fibromyalgia was previously defined by the American College of Rheumatology (ACR) 1990 classification criteria as widespread pain lasting for longer than three months with tenderness on palpation at 11 or more of 18 specified tender points (<a href="./references#CD012332-bbs2-0106" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(2):160‐72. [DOI: 10.1002/art.1780330203] ">Wolfe 1990</a>). For a clinical diagnosis, the ACR 1990 classification criteria (<a href="./references#CD012332-bbs2-0106" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(2):160‐72. [DOI: 10.1002/art.1780330203] ">Wolfe 1990</a>), and the ACR 2010 Preliminary Diagnostic Criteria (<a href="./references#CD012332-bbs2-0107" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62(5):600‐10. [DOI: 10.1002/acr.20140] ">Wolfe 2010</a>), can both be used. Lacking a specific laboratory test, diagnosis is established by a history of the key symptoms and the exclusion of somatic diseases sufficiently explaining the key symptoms (<a href="./references#CD012332-bbs2-0107" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62(5):600‐10. [DOI: 10.1002/acr.20140] ">Wolfe 2010</a>). The indexing of fibromyalgia within the International Classification of Diseases is under debate. While some rheumatologists have thought of it as a specific pain disorder and central sensitivity syndrome (<a href="./references#CD012332-bbs2-0018" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311(15):1547‐55. [DOI: 10.1001/jama.2014.3266] ">Clauw 2014</a>; <a href="./references#CD012332-bbs2-0113" title="YunusMB . Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism2008;37:339‐52. [DOI: 10.1016/j.semarthrit.2007.09.003] ">Yunus 2008</a>), research points at small fibre pathology in a subgroup of people with fibromyalgia that may be of pathophysiological (functional changes associated with or resulting from disease) importance (<a href="./references#CD012332-bbs2-0087" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154(11):2310‐6. [DOI: 10.1016/j.pain.2013.06.001] ">Oaklander 2013</a>; <a href="./references#CD012332-bbs2-0114" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel‐SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136(6):1857‐67. [DOI: 10.1093/brain/awt053] ">Üçeyler 2013a</a>). In psychiatry and psychosomatic medicine, fibromyalgia symptoms are categorised as a functional somatic syndrome, a bodily distress syndrome, a somatic physical symptom disorder, or a somatoform disorder (<a href="./references#CD012332-bbs2-0045" title="HäuserW , HenningsenP . Fibromyalgia syndrome ‐ a somatoform disorder?. European Journal of Pain2014;18(8):1052‐9. [DOI: 10.1002/j.1532‐2149.2014.00453.x] ">Häuser 2014a</a>). </p> <p>Fibromyalgia is a heterogeneous condition. The definite aetiology (causes) of this syndrome remains unknown. A model of interacting biological and psychosocial variables in the predisposition, triggering, and development of the chronicity of fibromyalgia symptoms has been suggested (<a href="./references#CD012332-bbs2-0096" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [Ätiologie und pathophysiologie des fibromyalgiesyndroms]. Schmerz2012;26(3):259‐67. [DOI: 10.1007/s00482‐012‐1174‐0] ">Sommer 2012a</a>). Depression (<a href="./references#CD012332-bbs2-0030" title="ForsethKO , HusbyG , GranJT , FørreO . Prognostic factors for the development of fibromyalgia in women with self‐reported musculoskeletal pain. A prospective study. Journal of Rheumatology1999;26:2458‐67. [PUBMED: 10555910] ">Forseth 1999</a>), genetics (<a href="./references#CD012332-bbs2-0011" title="ArnoldLM , FanJ , RussellIJ , YunusMB , KhanMA , KushnerI , et al. The fibromyalgia family study: a genome‐wide linkage scan study. Arthritis and Rheumatism2013;65:1122‐8. [DOI: 10.1002/art.37842] ">Arnold 2013</a>; <a href="./references#CD012332-bbs2-0056" title="LeeYH , ChoiSJ , JiJD , SongGG . Candidate gene studies of fibromyalgia: a systematic review and meta‐analysis. Rheumatology International2012;32(2):417‐26. [DOI: 10.1007/s00296‐010‐1678‐9] ">Lee 2012</a>), obesity combined with physical inactivity (<a href="./references#CD012332-bbs2-0083" title="MorkPJ , VasseljenO , NilsenTI . Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord‐Trøndelag Health Study. Arthritis Care &amp; Research2010;62:611‐7. ">Mork 2010</a>), physical and sexual abuse in childhood (<a href="./references#CD012332-bbs2-0041" title="HäuserW , KossevaM , ÜceylerN , KloseP , SommerC . Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta‐analysis. Arthritis Care and Research2011;63:808‐20. [DOI: 10.1002/acr.20328] ">Häuser 2011</a>), sleep problems (<a href="./references#CD012332-bbs2-0084" title="MorkPJ , NilsenTI . Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism2012;64(1):281‐4. [DOI: 10.1002/art.33346] ">Mork 2012</a>), and smoking predict future development of fibromyalgia (<a href="./references#CD012332-bbs2-0017" title="ChoiCJ , KnutsenR , OdaK , FraserGE , KnutsenSF . The association between incident self‐reported fibromyalgia and nonpsychiatric factors: 25‐years follow‐up of the Adventist Health Study. Journal of Pain2010;11:994‐1003. [DOI: 10.1016/j.jpain.2010.01.267] ">Choi 2010</a>). Psychosocial stress (working place and family conflicts) and physical stress (infections, surgery, accidents) might trigger the onset of chronic widespread pain and fatigue (<a href="./references#CD012332-bbs2-0018" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311(15):1547‐55. [DOI: 10.1001/jama.2014.3266] ">Clauw 2014</a>; <a href="./references#CD012332-bbs2-0096" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [Ätiologie und pathophysiologie des fibromyalgiesyndroms]. Schmerz2012;26(3):259‐67. [DOI: 10.1007/s00482‐012‐1174‐0] ">Sommer 2012a</a>). Depression and post‐traumatic stress disorder worsen fibromyalgia symptoms (<a href="./references#CD012332-bbs2-0043" title="HäuserW , GalekA , Erbslöh‐MöllerB , KöllnerV , Kühn‐BeckerH , LanghorstJ , et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain2013;154(8):1216‐23. [DOI: 10.1016/j.pain.2013.03.034] ">Häuser 2013a</a>; <a href="./references#CD012332-bbs2-0055" title="LangeM , PetermannF . Influence of depression on fibromyalgia: a systematic review [Einfluss von depression auf das fibromyalgiesyndrom: eine systematische literaturanalyse]. Schmerz2010;24(4):326‐33. [DOI: 10.1007/s00482‐010‐0937‐8] ">Lange 2010</a>). </p> <p>Several factors are associated with the pathophysiology of fibromyalgia, but the relationship is unclear. The functional changes include alteration of sensory processing in the brain, reduced reactivity of the hypothalamus‐pituitary‐adrenal axis to stress, increased pro‐inflammatory and reduced anti‐inflammatory cytokine profiles (produced by cells involved in inflammation), disturbances in neurotransmitters such as dopamine and serotonin, and small fibre pathology (<a href="./references#CD012332-bbs2-0087" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154(11):2310‐6. [DOI: 10.1016/j.pain.2013.06.001] ">Oaklander 2013</a>; <a href="./references#CD012332-bbs2-0096" title="SommerC , HäuserW , BurgmerM , EngelhardtR , GerholdK , PetzkeF , et al. Etiology and pathophysiology of fibromyalgia syndrome [Ätiologie und pathophysiologie des fibromyalgiesyndroms]. Schmerz2012;26(3):259‐67. [DOI: 10.1007/s00482‐012‐1174‐0] ">Sommer 2012a</a>; <a href="./references#CD012332-bbs2-0114" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel‐SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136(6):1857‐67. [DOI: 10.1093/brain/awt053] ">Üçeyler 2013a</a>). Prolonged exposure to stress, as outlined above, may contribute to these functional changes in predisposed individuals (<a href="./references#CD012332-bbs2-0015" title="BradleyLA . Pathophysiology of fibromyalgia. American Journal Medicine2009;122 (12 Suppl):S22‐30. [DOI: 10.1016/j.amjmed.2009.09.008] ">Bradley 2009</a>). </p> <p>People with fibromyalgia often report high disability levels and poor quality of life along with extensive use of medical care (<a href="./references#CD012332-bbs2-0047" title="HäuserW , AblinJ , FitzcharlesMA , LittlejonJ , LucianoJV , UsuiC , et al. Fibromyalgia. Nature Reviews Disease Primers2015;13(1):15022. [DOI: 10.1038/nrdp.2015.22] ">Häuser 2015</a>). Many people with fibromyalgia are significantly disabled, and experience moderate or severe pain for many years (<a href="./references#CD012332-bbs2-0012" title="BennettRM , JonesJ , TurkDC , RussellIJ , MatallanaL . An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders2007;8:27. [DOI: 10.1186/1471‐2474‐8‐27] ">Bennett 2007</a>). Chronic painful conditions comprised five of the 11 top‐ranking conditions for years lived with disability in 2010 (<a href="./references#CD012332-bbs2-0103" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 10.1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>), and are responsible for considerable loss of quality of life, employment, and increased health costs (<a href="./references#CD012332-bbs2-0079" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014a</a>). </p> <p>Fibromyalgia is common. One component of fibromyalgia, chronic widespread pain, is not only associated with other symptoms such as poor sleep, fatigue, and depression (<a href="./references#CD012332-bbs2-0110" title="WolfeF , WalittBT , HäuserW . What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research2014;66(7):969‐71. [DOI: 10.1002/acr.22207] ">Wolfe 2014a</a>), but also estimated to affect 11% of the general population (<a href="./references#CD012332-bbs2-0060" title="MansfieldKE , SimJ , JordanJL , JordanKP . A systematic review and meta‐analysis of the prevalence of chronic widespread pain in the general population. Pain2016;157(1):55‐64. [DOI: 10.1097/j.pain.0000000000000314] ">Mansfield 2016</a>). Numerous studies have investigated prevalence of fibromyalgia in different settings and countries. A review gave a global mean prevalence of potential cases of fibromyalgia of 2.7% (range 0.4% to 9.3%), with a mean in the Americas of 3.1%, in Europe of 2.5%, and in Asia of 1.7% (<a href="./references#CD012332-bbs2-0090" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5] ">Queiroz 2013</a>). Changes in diagnostic criteria do not appear to have significantly affected estimates of prevalence (<a href="./references#CD012332-bbs2-0109" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research2013;645(5):777‐85. [DOI: 10.1002/acr.21931] ">Wolfe 2013</a>). A survey using a modification of the 2010 ACR criteria found a prevalence of 1.8% in a large US survey, but 73% of these reported being given a different diagnosis by their physician (<a href="./references#CD012332-bbs2-0104" title="WalittB , NahinRL , KatzRS , BergmanMJ , WolfeF . The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One2015;10(9):e0138024. [DOI: 10.1371/journal.pone.0138024] ">Walitt 2015</a>). Estimates of prevalence in specific populations vary greatly, but have been reported to be as high as 9% in female textile workers in Turkey and 10% in metalworkers in Brazil (59% in those with repetitive strain injury; <a href="./references#CD012332-bbs2-0090" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5] ">Queiroz 2013</a>). When the 1990 ACR criteria are used for clinical surveys, women are more frequently diagnosed with the disorder. Using these criteria, the women to men ratio has ranged from 8:1 to 30:1 in people who were studied in clinical institutions and surveys. However, with criteria that do not use tender point examination, the sex ratio can be close to equal. The sex ratio has ranged from 4:1 to 1:1 in studies that were conducted in the general population using the research criteria for fibromyalgia (<a href="./references#CD012332-bbs2-0047" title="HäuserW , AblinJ , FitzcharlesMA , LittlejonJ , LucianoJV , UsuiC , et al. Fibromyalgia. Nature Reviews Disease Primers2015;13(1):15022. [DOI: 10.1038/nrdp.2015.22] ">Häuser 2015</a>; <a href="./references#CD012332-bbs2-0090" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5] ">Queiroz 2013</a>). </p> <p>Fibromyalgia pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any intervention. A multidisciplinary approach is recommended by evidence‐based guidelines, with pharmacological treatment being combined with physical or cognitive training, or both. Interventions aim to reduce the key symptoms of fibromyalgia (pain, sleep problems, fatigue) and the associated symptoms (depression, disability) and to improve daily functioning (<a href="./references#CD012332-bbs2-0024" title="EichW , HäuserW , ArnoldB , BernardyK , BrückleW , EidmannU , et al. Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz2012;26(3):268‐75. [DOI: 10.1007/s00482‐012‐1167‐z] ">Eich 2012</a>; <a href="./references#CD012332-bbs2-0029" title="FitzcharlesMA , Ste‐MariePA , GoldenbergDL , PereiraJX , AbbeyS , ChoinièreM , et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research Management2013;18(3):119‐26. [PUBMED: 23748251] ">Fitzcharles 2013</a>). Conventional analgesics are usually not effective. Treatment is often offered with antidepressants such as serotonin and noradrenaline reuptake inhibitors (<a href="./references#CD012332-bbs2-0044" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292] ">Häuser 2013b</a>; <a href="./references#CD012332-bbs2-0057" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] ">Lunn 2014</a>), tricyclic agents such as amitriptyline (<a href="./references#CD012332-bbs2-0075" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] ">Moore 2012a</a>), or anticonvulsants such as gabapentin or pregabalin (<a href="./references#CD012332-bbs2-0072" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011a</a>; <a href="./references#CD012332-bbs2-0115" title="ÜçeylerN , SommerC , WalittB , HäuserW . Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010782] ">Üçeyler 2013b</a>; <a href="./references#CD012332-bbs2-0105" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013</a>). The proportion of people who achieve worthwhile pain relief (typically at least 50% reduction in pain intensity) is small (<a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>), and generally reaches only 10% to 15% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNTs) of about 7 to 10 (<a href="./references#CD012332-bbs2-0050" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339. [DOI: 10.1136/bmj.f7339] ">Kalso 2013</a>; <a href="./references#CD012332-bbs2-0105" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013</a>). With some treatments, people who experience a good level of pain relief also report substantial reductions in other symptoms, such as fatigue, sleep problems, depression and anxiety, and also experience significant improvement in quality of life, function and ability to work (<a href="./references#CD012332-bbs2-0069" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] ">Moore 2010b</a>; <a href="./references#CD012332-bbs2-0100" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471‐2474‐12‐125] ">Straube 2011</a>). Fibromyalgia is not particularly different from other chronic pain with regard to a small proportion of trial participants having a good response to analgesic treatment (<a href="./references#CD012332-bbs2-0078" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). </p> </section> <section id="CD012332-sec-0032"> <h3 class="title" id="CD012332-sec-0032">Description of the intervention</h3> <p>Nonsteroidal anti‐inflammatory drugs (NSAIDs) are the most commonly used analgesics (<a href="./references#CD012332-bbs2-0054" title="LaineL . Approaches to nonsteroidal anti‐inflammatory drug use in the high‐risk patient. Gastroenterology2001;120(3):594‐606. [DOI: 10.1053/gast.2001.21907] ">Laine 2001</a>). NSAIDs act by inhibiting the cyclooxygenases (COXs), which synthesise prostaglandins that are involved in inflammation and pain. The analgesic and anti‐inflammatory actions of NSAIDs are attributed to the inhibition of cyclooxygenase‐2 (COX‐2), while their adverse gastrointestinal effects are attributed to the inhibition of cyclooxygenase‐1 (COX‐1). Traditional NSAIDs such as ibuprofen are non‐selective. COX‐2‐selective NSAIDs were thus developed to reduce adverse gastrointestinal effects, but were later considered to increase the risk of myocardial infarction and stroke (<a href="./references#CD012332-bbs2-0014" title="Coxib and traditional NSAID Trialists' (CNT) Collaboration, BhalaN , EmbersonJ , MerhiA , AbramsonS , ArberN , et al. Vascular and upper gastrointestinal effects of non‐steroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2014;382(9894):769‐79. [DOI: 10.1016/S0140‐6736(13)60900‐9] ">Bhala 2014</a>), and some drugs were withdrawn (<a href="./references#CD012332-bbs2-0025" title="European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf (accessed 23 August 2016)2005. ">EMEA 2005</a>; <a href="./references#CD012332-bbs2-0028" title="Food , DrugAdministration . FDA Public Health Advisory: safety of Vioxx. www.fda.gov/drugs/drugSafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106274.htm (accessed 23 August 2016)2004. ">FDA 2004</a>). Whether available drugs increase the risk of cardiovascular effects is a matter of dispute, with the randomised trial evidence pointing to some increased risk for many (<a href="./references#CD012332-bbs2-0014" title="Coxib and traditional NSAID Trialists' (CNT) Collaboration, BhalaN , EmbersonJ , MerhiA , AbramsonS , ArberN , et al. Vascular and upper gastrointestinal effects of non‐steroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet2014;382(9894):769‐79. [DOI: 10.1016/S0140‐6736(13)60900‐9] ">Bhala 2014</a>), while large‐scale observational studies can point to no increased risk or even a reduced risk of serious harm (<a href="./references#CD012332-bbs2-0059" title="MangoniAA , WoodmanRJ , GaganisP , GilbertAL , KnightsKM . Use of non‐steroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology2010;69(6):689‐700. [DOI: 10.1111/j.1365‐2125.2010.03627.x] ">Mangoni 2010</a>). The balance of benefits and risks is fine (<a href="./references#CD012332-bbs2-0080" title="MooreRA , DerryS , SimonLS , EmeryP . Nonsteroidal anti‐inflammatory drugs, gastroprotection, and benefit‐risk. Pain Practice2014;14(4):378‐95. [DOI: 10.1111/papr.12100] ">Moore 2014b</a>). </p> </section> <section id="CD012332-sec-0033"> <h3 class="title" id="CD012332-sec-0033">How the intervention might work</h3> <p>One current hypothesis is that damage to the peripheral nerves is followed by an inflammatory reaction that relates to increased production of prostaglandins, amplifying sodium currents and calcium influx in peripheral nociceptive neurons, and enhancing neurotransmitter release in the central nervous system (CNS) and depolarisation of second‐order nociceptive neurons (<a href="./references#CD012332-bbs2-0102" title="VoT , RiceASC , DworkinRH . Non‐steroidal anti‐inflammatory drugs for neuropathic pain: how do we explain continued widespread use?. Pain2009;143(3):169‐71. [DOI: 10.1016/j.pain.2009.03.013] ">Vo 2009</a>). Preclinical data suggest an immune pathogenesis of neuropathic pain, but clinical evidence of a central role of the immune system is less clear (<a href="./references#CD012332-bbs2-0016" title="CalvoM , DawesJM , BennettDL . The role of the immune system in the generation of neuropathic pain. Lancet Neurology2012;11(7):629‐42. [DOI: 10.1016/S1474‐4422(12)70134‐5] ">Calvo 2012</a>). NSAIDs inhibit the production of prostaglandins, and thus could lessen the peripheral and central sensory hypersensitivity that occurs with nerve injury‐associated inflammation. NSAIDs have been shown to reduce sensory hypersensitivity in animal models (<a href="./references#CD012332-bbs2-0036" title="HasnieFS ,  BreuerJ ,  ParkerS ,  WallaceV ,  BlackbeardJ ,  LeverI ,  etal . Further characterization of a rat model of varicella zoster virus‐associated pain: relationship between mechanical hypersensitivity and anxiety‐related behavior, and the influence of analgesic drugs. Neuroscience2007;144(4):1495‐508. [DOI: 10.1016/j.neuroscience.2006.11.029] ">Hasnie 2007</a>; <a href="./references#CD012332-bbs2-0051" title="KawakamiM ,  MatsumotoT ,  HashizumeH ,  KuribayashiK ,  TamakiT . Epidural injection of cyclooxygenase‐2 inhibitor attenuates pain‐related behavior following application of nucleus pulposus to the nerve root in the rat. Journal of Orthopaedic Research2002;20(2):376‐81. [DOI: 10.1016/S0736‐0266(01)00114‐0] ">Kawakami 2002</a>). These putative mechanisms may also have relevance to fibromyalgia because of possible CNS inflammation in people with fibromyalgia (<a href="./references#CD012332-bbs2-0031" title="GeissA , RohlederN , AntonF . Evidence for an association between an enhanced reactivity of interleukin‐6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology2012;37(5):671‐85. [DOI: 10.1016/j.psyneuen.2011.07.021] ">Geiss 2012</a>; <a href="./references#CD012332-bbs2-0049" title="KadetoffD , LampaJ , WestmanM , AnderssonM , KosekE . Evidence of central inflammation in fibromyalgia‐increased cerebrospinal fluid interleukin‐8 levels. Journal of Neuroimmunology2012;242(1‐2):33‐8. [DOI: 10.1016/j.jneuroim.2011.10.013] ">Kadetoff 2012</a>), and because people with neuropathic pain and fibromyalgia can experience very similar sensory phenomena (<a href="./references#CD012332-bbs2-0052" title="KoroschetzJ , RehmSE , GockelU , BroszM , FreynhagenR , TölleTR , et al. Fibromyalgia and neuropathic pain ‐ differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology2011;11:55. [DOI: 10.1186/1471‐2377‐11‐55] ">Koroschetz 2011</a>). </p> </section> <section id="CD012332-sec-0034"> <h3 class="title" id="CD012332-sec-0034">Why it is important to do this review</h3> <p>NSAIDs are widely used in the treatment of fibromyalgia, despite weak evidence of efficacy in this condition. A telephone survey of women with fibromyalgia found that about 30% were taking NSAIDs, compared with only 8% of women without fibromyalgia (<a href="./references#CD012332-bbs2-0095" title="ShaverJL , WilburJ , LeeH , RobinsonFP , WangE . Self‐reported medication and herb/supplement use by women with and without fibromyalgia. Journal of Womens Health2009;18(5):709‐16. [DOI: 10.1089/jwh.2008.1194] ">Shaver 2009</a>). Over 3000 US adults with fibromyalgia participated in an 11‐year longitudinal study of fibromyalgia outcomes, and while NSAID use fell over the period, it was still 44% in 2010 (<a href="./references#CD012332-bbs2-0111" title="WolfeF , WalittBT , KatzRS , LeeYC , MichaudKD , HäuserW . Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain2014;17(4):581‐6. [DOI: 10.1002/j.1532‐2149.2012.00234.x] ">Wolfe 2014b</a>), and analgesics including NSAIDs are frequently used in Germany (<a href="./references#CD012332-bbs2-0042" title="HäuserW , JungE , Erbslöh‐MöllerB , GesmannM , Kühn‐BeckerH , PetermannF , et al. The German fibromyalgia consumer reports ‐ a cross‐sectional survey. BMC Musculoskeletal Disorders2012;13:74. [DOI: 10.1186/1471‐2474‐13‐74] ">Häuser 2012</a>). This is despite the recommendations of the European League against Rheumatism (EULAR), the American Pain Society (APS), and the Association of Medical Societies of Germany (AWMF) recommending that NSAIDs are not used to treat fibromyalgia (<a href="./references#CD012332-bbs2-0040" title="HäuserW , ThiemeK , TurkDC . Guidelines on the management of fibromyalgia syndrome ‐ a systematic review. European Journal of Pain2010;14(1):5‐10. [DOI: 10.1016/j.ejpain.2009.01.006] ">Häuser 2010</a>). Of course, NSAIDs may be used to treat people with fibromyalgia who have concomitant musculoskeletal conditions for which NSAID use is appropriate. </p> <p>We are unaware of any systematic review specifically relating to the efficacy of NSAIDs in fibromyalgia, though broader reviews have identified a general lack of evidence (<a href="./references#CD012332-bbs2-0046" title="HäuserW , WalittB , FitzcharlesMA , SommerC . Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research and Therapy2014;16(1):201. [DOI: 10.1186/ar4441] ">Häuser 2014b</a>), or not addressed NSAIDs (<a href="./references#CD012332-bbs2-0085" title="NüeschE , HäuserW , BernardyK , BarthJ , JüniP . Comparative efficacy of pharmacological and non‐pharmacological interventions in fibromyalgia syndrome: network meta‐analysis. Annals of the Rheumatic Diseases2013;72(6):955‐62. [DOI: 10.1136/annrheumdis‐2011‐201249] ">Nüesch 2013</a>). </p> <p>In addition, the standards used to assess evidence in chronic pain trials have changed substantially, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using average pain scores, or average change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of eight to 12 weeks or longer. Pain intensity reduction of 50% or more has been shown to correlate with improvements in comorbid symptoms, function, and health‐related quality of life generally for acute and chronic pain (<a href="./references#CD012332-bbs2-0020" title="ConaghanPG , PelosoPM , EverettSV , RajagopalanS , BlackCM , MavrosP , et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real‐world therapies. Rheumatology (Oxford)2015;54(2):270‐7. [DOI: 10.1093/rheumatology/keu332] ">Conaghan 2015</a>; <a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>; <a href="./references#CD012332-bbs2-0089" title="PelosoPM , MooreRA , ChenWJ , LinHY , GatesDF , StrausWL , et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scandinavian Journal of Pain2016;13(10):175‐81. [DOI: 10.1016/j.sjpain.2016.07.002] ">Peloso 2016</a>), and specifically for fibromyalgia (<a href="./references#CD012332-bbs2-0070" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010c</a>; <a href="./references#CD012332-bbs2-0100" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471‐2474‐12‐125] ">Straube 2011</a>). These standards are set out in the reference guide for pain studies (<a href="./references#CD012332-bbs2-0088" title="Pain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 23 August 2016). ">PaPaS 2012</a>). </p> <p>This Cochrane Review will assess evidence using methods that make both statistical and clinical sense, and will use developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012332-bbs2-0068" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). The trials included and analysed will need to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc), and size (ideally at least 500 participants in a comparison in which the NNT is 4 or above; <a href="./references#CD012332-bbs2-0065" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). This approach sets high standards and marks a departure from how reviews were conducted previously. The use of unbiased trials reduces the chances of overestimating treatment effects (<a href="./references#CD012332-bbs2-0063" title="MillsEJ , AyersD , ChouR , ThorlundK . Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?. Contemporary Clinical Trials2015;45(Pt A):2‐7. [DOI: 10.1016/j.cct.2015.07.019] ">Mills 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012332-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012332-sec-0035"></div> <p>To assess the analgesic efficacy, tolerability (drop‐out due to adverse events), and safety (serious adverse events) of oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012332-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012332-sec-0036"></div> <section id="CD012332-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012332-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with double‐blind assessment of participant outcomes following two weeks of treatment or longer, although the emphasis of the review was on studies with a duration of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results, summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were not randomised, studies of experimental pain, case reports, and clinical observations. </p> <p>Trials needed at least 10 participants per treatment arm. The protocol required a minimum of 20 participants per arm because of growing evidence of bias in small studies (<a href="./references#CD012332-bbs2-0021" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;f2304:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD012332-bbs2-0022" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312(6):623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012332-bbs2-0065" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). We amended this in order to review all available information where there was so little. </p> </section> <section id="CD012332-sec-0039"> <h4 class="title">Types of participants</h4> <p>Studies included adults aged 18 years and above, diagnosed with fibromyalgia using the ACR 1990 classification criteria (<a href="./references#CD012332-bbs2-0106" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(2):160‐72. [DOI: 10.1002/art.1780330203] ">Wolfe 1990</a>), the ACR 2010 Preliminary Diagnostic Criteria (<a href="./references#CD012332-bbs2-0107" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62(5):600‐10. [DOI: 10.1002/acr.20140] ">Wolfe 2010</a>), or the modified ACR 2010 preliminary diagnostic criteria (research criteria) (<a href="./references#CD012332-bbs2-0081" title="MooreRA , CaiN , SkljarevskiV , TölleTR . Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain2014;18(1):67‐75. [DOI: 10.1002/j.1532‐2149.2013.00341.x] ">Moore 2014c</a>; <a href="./references#CD012332-bbs2-0108" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology2011;38:1113‐22. [DOI: 10.3899/jrheum.100594] ">Wolfe 2011</a>). We also considered other diagnostic criteria for older studies. </p> </section> <section id="CD012332-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Oral NSAID, at any dose, administered for the relief of fibromyalgia pain, and compared to placebo or any active comparator. </p> </section> <section id="CD012332-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with the majority using standard subjective scales (numerical rating scale or visual analogue scale) for pain intensity or pain relief, or both. We were particularly interested in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD012332-bbs2-0023" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These dichotomous outcomes should be used where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (<a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>; <a href="./references#CD012332-bbs2-0086" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x] ">O'Brien 2010</a>). </p> <section id="CD012332-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012332-list-0001"> <li> <p>Participant‐reported pain relief of 50% or greater or PGIC very much improved (substantial improvement) </p> </li> <li> <p>Participant‐reported pain relief of 30% or greater or PGIC much or very much improved (moderate improvement) </p> </li> <li> <p>Safety: participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the person, or may require an intervention to prevent one of the above characteristics or consequences. </p> </li> <li> <p>Tolerability: withdrawals due to adverse events</p> </li> </ul> </p> </section> <section id="CD012332-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012332-list-0002"> <li> <p>Participants experiencing any adverse event</p> </li> <li> <p>Withdrawals due to lack of efficacy and for any cause</p> </li> <li> <p>Participant‐reported improvement of health‐related quality of life in the Fibromyalgia Impact Questionnaire (FIQ) of 14% or greater (<a href="./references#CD012332-bbs2-0013" title="BennettRM , BushmakinAG , CappelleriJC , ZlatevaG , SadoskyAB . Minimal clinically important difference in the fibromyalgia impact questionnaire. Journal of Rheumatology2009;36:1304‐11. [DOI: 10.3899/jrheum.081090] ">Bennett 2009</a>) </p> </li> <li> <p>Specific adverse events using the Medical Dictionary for Regulatory Activities (MedDRA) classification, where reported (<a href="http://www.meddra.org" target="_blank">www.meddra.org</a>) </p> </li> <li> <p>Outcomes (expected to be continuous variables) relating to sleep problems, depression, anxiety, and fatigue </p> </li> </ul> </p> </section> </section> </section> <section id="CD012332-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012332-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases, without language restrictions.</p> <p> <ul id="CD012332-list-0003"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (via Cochrane Register of Studies Online) (6 January 2017) (<a href="./appendices#CD012332-sec-0103">Appendix 2</a>) </p> </li> <li> <p>MEDLINE (via Ovid) (1946 to 6 January 2017) (<a href="./appendices#CD012332-sec-0104">Appendix 3</a>) </p> </li> <li> <p>Embase (via Ovid) (1974 to 6 January 2017) (<a href="./appendices#CD012332-sec-0105">Appendix 4</a>) </p> </li> <li> <p>Oxford Pain Relief Database (<a href="./references#CD012332-bbs2-0048" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [DOI: doi.org/10.1016/0197‐2456(95)00134‐4] ">Jadad 1996</a>) </p> </li> </ul> </p> </section> <section id="CD012332-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We examined the bibliographies of any RCTs identified and review articles, and searched clinical trials databases (ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>) and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>)) to identify additional published or unpublished data. We did not routinely contact investigators or study sponsors. </p> </section> </section> <section id="CD012332-sec-0047"> <h3 class="title" id="CD012332-sec-0047">Data collection and analysis</h3> <section id="CD012332-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors made the decisions. At least two review authors read these studies independently and reached agreement by discussion if necessary. We did not anonymise the studies before assessment. A PRISMA flow chart shows the study flow (<a href="./references#CD012332-bbs2-0064" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). </p> </section> <section id="CD012332-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently using a standard form and checked for agreement before entry into Review Manager 5 (<a href="./references#CD012332-bbs2-0091" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), or any other analysis tool. We included information about the pain condition and number of participants treated, drug and dosing regimen, control intervention, study design, study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event, specific adverse events, or a serious adverse event). </p> </section> <section id="CD012332-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD012332-bbs2-0048" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [DOI: doi.org/10.1016/0197‐2456(95)00134‐4] ">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. </p> <p>Two review authors independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012332-bbs2-0038" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), and adapted from those used by Cochrane Pregnancy and Childbirth, with any disagreements resolved by discussion. </p> <p>We assessed the following for each study.</p> <p> <ul id="CD012332-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, random number table; computer random‐number generator); unclear risk of bias (when the method used to generate the sequence was not clearly stated). We excluded studies at a high risk of bias that used a non‐random process (odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively‐numbered, sealed, opaque envelopes); unclear risk of bias (when method not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study stated identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We only accepted studies where assessment of pain and symptoms such as fatigue or sleep problems was self‐reported by participants, and assessed the methods used to blind study participants and any outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how this was achieved); unclear risk of bias (study stated that outcome assessors were blind to treatment allocation but lacked a clear statement on how it was achieved). We excluded studies where outcome assessment was not blinded. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (fewer than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). </p> </li> <li> <p>Reporting bias due to selective outcome reporting: we checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. We assigned a low risk of reporting bias if the study protocol was available and all of the study's prespecified (primary and secondary) outcomes that were of interest in the review had been reported in the prespecified way, or if the study protocol was not available but it was clear that the published reports contained all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon). We assigned a high risk of reporting bias if not all of the study's prespecified primary outcomes had been reported; one or more primary outcomes was reported using measurements, analysis methods, or subsets of the data (subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse event); one or more outcomes of interest in the review was reported incompletely so that it could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study. </p> </li> <li> <p>Group similarity at baseline (selection bias): we assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. We assigned a low risk of bias if groups were similar at baseline for demographic factors, value of main outcome measure(s), baseline symptoms relevant to main outcomes, and important prognostic factors. We assigned a high risk of bias if groups were not similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors. </p> </li> </ul> </p> </section> <section id="CD012332-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We used dichotomous data to calculate risk difference (RD) with 95% confidence intervals (CI) using a fixed‐effect model. We calculated NNTs as the reciprocal of the absolute risk difference (<a href="./references#CD012332-bbs2-0061" title="McQuayH , MooreR . An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐262718‐X] ">McQuay 1998</a>). For unwanted effects, the number needed to treat for an additional beneficial outcome becomes the number needed to treat for an additional harmful outcome (NNH) and is calculated in the same manner. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD012332-list-0005"> <li> <p>When significantly fewer adverse outcomes occurred with treatment than with control (placebo or active), we used the term the<i>'</i>number needed to treat to prevent one event' (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with treatment compared with control (placebo or active), we used the term the 'number needed to treat for an additional harmful outcome or to cause one event' (NNH). </p> </li> </ul> </p> <p>For continuous data, we calculated standardised mean differences (SMDs) with 95% CIs using a random‐effects model because we anticipated clinical heterogeneity. We planned to use Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g of 0.2 = small, 0.5 = medium, and 0.8 = large (<a href="./references#CD012332-bbs2-0019" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. Abingdon, UK: Lawrence Erlbaum Associates, 1988. [ISBN: 978‐0805802832] ">Cohen 1988</a>). We would regard g less than 0.2 to be a 'not substantial' effect size. We assumed a minimally important difference if Hedges' g was 0.2 or greater (<a href="./references#CD012332-bbs2-0027" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Research2014;23(1):1‐4. [DOI: 10.1007/s11136‐013‐0443‐4] ">Fayers 2014</a>). </p> <p>The threshold for 'clinically relevant benefit' or 'clinically relevant harm' was set for categorical variables by an absolute risk reduction or increase of 10% or greater corresponding an NNT or NNH of 10 or less (<a href="./references#CD012332-bbs2-0066" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). The threshold 'clinically relevant benefit' was set for continuous variables by an effect size more than 0.2 (<a href="./references#CD012332-bbs2-0027" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Research2014;23(1):1‐4. [DOI: 10.1007/s11136‐013‐0443‐4] ">Fayers 2014</a>). </p> </section> <section id="CD012332-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. If two active treatment arms were separately compared with a single control arm in an analysis, we would split the total number in the control arm between the active arms to avoid double counting. </p> </section> <section id="CD012332-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We used an intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post‐baseline assessment. We would assign missing participants zero improvement. </p> </section> <section id="CD012332-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity by combining studies that examined similar diagnostic criteria for fibromyalgia. We planned to assess statistical heterogeneity visually (<a href="./references#CD012332-bbs2-0053" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. [DOI: 10.7326/0003‐4819‐107‐2‐224] ">L'Abbé 1987</a>), and with the I<sup>2</sup> statistic (<a href="./references#CD012332-bbs2-0037" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). When the I<sup>2</sup> value was greater than 50%, we would consider possible reasons for this. </p> </section> <section id="CD012332-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous pain outcomes of known utility and of value to people with fibromyalgia (<a href="./references#CD012332-bbs2-0039" title="HoffmanDL , SadoskyA , DukesEM , AlvirJ . How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] ">Hoffman 2010</a>; <a href="./references#CD012332-bbs2-0069" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] ">Moore 2010b</a>; <a href="./references#CD012332-bbs2-0070" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010c</a>; <a href="./references#CD012332-bbs2-0071" title="MooreRA , SmugarSS , WangH , PelosoPM , GammaitoniA . Numbers‐needed‐to‐treat analyses ‐ do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain2010;151(3):592‐7. [DOI: 10.1016/j.pain.2010.07.013] ">Moore 2010d</a>; <a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). The review did not depend on what the authors of the original studies chose to report or not, though clearly difficulties arose in studies that did not report any dichotomous results. We extracted and used continuous data for pain, which probably reflect efficacy and utility poorly, but which may be useful for illustrative purposes. </p> <p>We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result for pain clinically irrelevant (usually taken to mean an NNT of 10 or higher; <a href="./references#CD012332-bbs2-0066" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). </p> </section> <section id="CD012332-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We planned to use a fixed‐effect model for meta‐analysis because we did not anticipate considerable clinical homogeneity. We would use a random‐effects model for meta‐analysis if there was significant clinical heterogeneity and it was considered appropriate to combine studies. </p> <section id="CD012332-sec-0057"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE approach to assess the quality of evidence related to each of the key outcomes, and report our judgement on the quality of the evidence in <a href="./full#CD012332-tbl-0001">summary of findings Table for the main comparison</a> (<a href="./references#CD012332-bbs2-0093" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>; <a href="./appendices#CD012332-sec-0106">Appendix 5</a>). </p> <p>We paid particular attention to inconsistency, where point estimates varied widely across studies or confidence intervals of studies showed minimal or no overlap (<a href="./references#CD012332-bbs2-0033" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Cinical Epidemiology2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011</a>), and potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD012332-bbs2-0066" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012332-bbs2-0034" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>). For example, if there were so few data that the results were highly susceptible to the random play of chance, or if a study used LOCF imputation in circumstances where there were substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by 3 levels, to very low quality. In circumstances where there were no data reported for an outcome, we would report the level of evidence as very low quality (<a href="./references#CD012332-bbs2-0035" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>). </p> </section> <section id="CD012332-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We have included a 'Summary of findings' table as set out in the PaPaS author guide (<a href="./references#CD012332-bbs2-0088" title="Pain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 23 August 2016). ">PaPaS 2012</a>), and recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012332-bbs2-0094" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). The table includes, where possible, outcomes equivalent to moderate or substantial benefit of at least 30% and at least 50% pain intensity reduction, PGIC (possibly at least substantial improvement and at least moderate improvement) (<a href="./references#CD012332-bbs2-0023" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>), withdrawals due to lack of efficacy, withdrawals due to adverse events, serious adverse events, and death (a particular serious adverse event). </p> <p>For the 'Summary of findings' table we used the following descriptors for levels of evidence (<a href="./references#CD012332-bbs2-0026" title="EffectivePractice , Organisation of Care(EPOC) . EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services2015; Vol. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>): </p> <p> <ul id="CD012332-list-0006"> <li> <p><b>High:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is low. </p> </li> <li> <p><b>Moderate:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is moderate. </p> </li> <li> <p><b>Low:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>a</sup> is high. </p> </li> <li> <p><b>Very low:</b> tThis research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is very high. </p> </li> </ul> </p> <p><sup>a</sup>Substantially different: a large enough difference that it might affect a decision. </p> </section> </section> <section id="CD012332-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Possible issues for subgroup analysis were drug, dose, and formulation. A minimum of two studies and 200 participants would have to have been available for any subgroup analysis. </p> <p>We also planned to consider a subgroup analysis according to the inclusion and exclusion criteria of included studies, because a major limitation of most drug trials in fibromyalgia is the exclusion of people with mental disorders and relevant medical diseases. </p> </section> <section id="CD012332-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned no sensitivity analysis because the evidence base was known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012332-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012332-sec-0061"></div> <section id="CD012332-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012332-sec-0063"> <h4 class="title">Results of the search</h4> <p>We found 10 studies in our electronic searches for which we obtained full‐text articles for detailed assessment. Of these, we included six and excluded four (<a href="#CD012332-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012332-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012332-sec-0064"> <h4 class="title">Included studies</h4> <p>We included six studies in our review as randomised, double‐blind studies in suitably characterised fibromyalgia (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). In these studies the mean age of participants was between 39 and 50 years, and 89% to 100% were women. The initial pain intensity was recorded as between 60% and 75% of the maximum on the scale (equivalent to 6.0 to 7.5 on a 0 to 10 numerical rating scale (NRS)). </p> <p>Participants excluded from the studies were those typical of chronic pain studies with NSAIDs ‐ pregnancy, breast feeding, previous peptic ulcer or bleeding, sensitivity or allergy, or serious medical conditions or (in <a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>) major psychiatric disorder. Of note, four studies explicitly excluded participants with inflammatory rheumatic diseases (<a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>) and one other study (<a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>) probably did so. Most probably, four studies excluded participants with osteoarthritis (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). </p> <p>Diagnostic criteria used were those of <a href="./references#CD012332-bbs2-0112" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151‐71. ">Yunus 1981</a> (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>), ACR 1990 (<a href="./references#CD012332-bbs2-0106" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(2):160‐72. [DOI: 10.1002/art.1780330203] ">Wolfe 1990</a>) (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>), and <a href="./references#CD012332-bbs2-0092" title="RussellIJ , VipraioGA , MorganWW , BowdenCL . Is there a metabolic basis for the fibrositis syndrome?. American Journal of Medicine1986;81(Suppl 3A):50‐54. ">Russell 1986</a> (<a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>); <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a> noted that almost all included participants also met the diagnostic criteria of ACR 1990 and <a href="./references#CD012332-bbs2-0112" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151‐71. ">Yunus 1981</a>. Studies were all conducted in an outpatient setting, in Israel, Spain, and the USA. All the studies reported some degree of industry funding. </p> <p>NSAIDs tested were etoricoxib 90 mg daily (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>), ibuprofen 2400 mg daily (<a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>), naproxen 1000 mg daily (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>), and tenoxicam 20 mg daily (<a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>). In these parallel‐group studies, 146 participants received NSAID and 146 placebo. The duration of treatment in the double‐blind phase varied; three weeks (<a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>), five weeks (<a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>), six weeks (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>), and eight weeks (<a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>). All NSAIDs and analgesics were discontinued between three days and three weeks before the initial visit. </p> <p>Data extracted from the six included studies are in <a href="./appendices#CD012332-sec-0107">Appendix 6</a>. </p> </section> <section id="CD012332-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded four full‐text articles because they were not double‐blind (<a href="./references#CD012332-bbs2-0008" title="FossaluzzaV , DeVitaS . Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. International Journal of Clinical Pharmacology Research1992;12(2):99‐102. ">Fossaluzza 1992</a>), or because the condition studied was not fibromyalgia (<a href="./references#CD012332-bbs2-0007" title="DonaldJF , Layes MollaA . A comparative double‐blind study of tiaprofenic acid and aspirin in the treatment of muscular rheumatism, fibrositis, sprains and soft tissue injuries in general practice. Journal of International Medical Research1980;8(6):382‐7. ">Donald 1980</a>; <a href="./references#CD012332-bbs2-0009" title="LeGallezP , ReeveFB , CrawleyMA , BirdHA . A double‐blind comparison of ibuprofen, placebo and ibuprofen with meptazinol in soft tissue rheumatism. Current Medical Research and Opinion1988;10(10):663‐7. ">Le Gallez 1988</a>; <a href="./references#CD012332-bbs2-0010" title="SchornD . Tenoxicam in soft‐tissue rheumatism. South African Medical Journal1986;69(5):301‐3. ">Schorn 1986</a>). </p> </section> </section> <section id="CD012332-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Oxford Quality Scores were 3/5 for four studies and 4/5 for two studies. Results for risk of bias are shown in <a href="#CD012332-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012332-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012332-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD012332-sec-0067"> <h4 class="title">Allocation</h4> <p>No study adequately described the method of allocation or allocation concealment.</p> </section> <section id="CD012332-sec-0068"> <h4 class="title">Blinding</h4> <p>Only one study gave details to indicate that placebo and active drugs were matched (<a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). Participants reported their own pain scores in all studies, and these were consequently assessed as low risk of bias for efficacy, but their assessment of adverse events was generally unclear. </p> </section> <section id="CD012332-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>For three studies we considered risk of bias low, because data on all participants seemed sensibly reported (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). For one, the use of LOCF imputation meant that we judged this unclear (<a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>), and for two we judged the risk of bias high because most secondary outcomes were not reported or because the results reported were of a completer analysis (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>). </p> </section> <section id="CD012332-sec-0070"> <h4 class="title">Selective reporting</h4> <p>We judged selective reporting as low risk, as our interest was not what was reported, but what outcomes are important to participants with chronic pain, including fibromyalgia (<a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> </section> <section id="CD012332-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>Groups were generally similar at baseline, or this was not reported in sufficient detail. In each study the group size was below 50 participants in each treatment arm, leading to a judgement of high risk of bias in all studies. </p> </section> </section> <section id="CD012332-sec-0072"> <h3 class="title" id="CD012332-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD012332-tbl-0001"><b>Summary of findings for the main comparison</b> NSAID compared with placebo for fibromyalgia</a> </p> <p>No study reported any significant efficacy difference between NSAID and placebo on any measure. Few reported the measures of interest. <a href="./full#CD012332-tbl-0001">summary of findings Table for the main comparison</a> summarises the results. </p> <section id="CD012332-sec-0073"> <h4 class="title">Pain relief of 50% or greater or PGIC very much improved (substantial improvement)</h4> <p>This was reported by two studies (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>), though for one we chose to interpret a reported clinically significant improvement as substantial improvement, as the study also reported 25% pain reduction in a larger number of participants (<a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>). </p> <p> <ul id="CD012332-list-0007"> <li> <p>The proportion of participants with substantial improvement at study end with NSAID was 11% (8/73). </p> </li> <li> <p>The proportion of participants with substantial improvement at study end with placebo was 18% (13/73). </p> </li> <li> <p>The RD for NSAID compared with placebo was ‐0.07 (95% CI ‐0.18 to 0.04) (<a href="./references#CD012332-fig-0003" title="">Analysis 1.1</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome by three levels to very low quality because of the small size of studies and pooled data set, and because there were only 21 actual events in the analysis. </p> </section> <section id="CD012332-sec-0074"> <h4 class="title">Pain relief of 30% or greater or PGIC much or very much improved (moderate improvement)</h4> <p>This was reported by three studies (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>), and we chose to interpret as moderate improvement a 25% pain reduction (<a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>). </p> <p> <ul id="CD012332-list-0008"> <li> <p>The proportion of participants with moderate improvement at study end with NSAID was 22% (21/95). </p> </li> <li> <p>The proportion of participants with moderate improvement at study end with placebo was 26% (25/97). </p> </li> <li> <p>The RD for NSAID compared with placebo was ‐0.04 (95% CI ‐0.16 to 0.08) (<a href="./references#CD012332-fig-0004" title="">Analysis 1.2</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome by three levels to very low quality because of the small size of studies and pooled data set, and because there were only 46 actual events in the analysis. </p> </section> <section id="CD012332-sec-0075"> <h4 class="title">Serious adverse events</h4> <p>No serious adverse events were reported in any study, apart from a single case of sedation, memory problems, and impaired mentation (<a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>). Whether this should be classified as serious is unclear from the report. It was considered a typical benzodiazepine adverse event in a study where benzodiazepines were also being used. This participant was not taking benzodiazepines, but the response diminished when the placebo benzodiazepine dose was reduced. </p> <p>No trial mentioned any deaths occurring.</p> <p>We assessed the quality of the evidence as very low quality because of the very small number of events, or no events in the case of death. </p> </section> <section id="CD012332-sec-0076"> <h4 class="title">Withdrawals due to adverse events</h4> <p>Adverse event withdrawals were reported in all studies. Two did not report withdrawals by treatment group (<a href="./references#CD012332-bbs2-0002" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia‐report of a double‐blind placebo‐controlled study. Journal of Musculoskeletal Pain1994;2(1):3‐27. ">Kravitz 1994</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>), but four did (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). </p> <p> <ul id="CD012332-list-0009"> <li> <p>The proportion of participants withdrawing because of an adverse event with NSAID was 5% (6/114). </p> </li> <li> <p>The proportion of participants withdrawing because of an adverse event with placebo was 2% (2/116). </p> </li> <li> <p>The RD for NSAID compared with placebo was 0.04 (95% CI ‐0.02 to 0.09) (<a href="./references#CD012332-fig-0005" title="">Analysis 1.3</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome by three levels to very low quality because of the small size of studies and pooled data set, and because there were only eight actual events in the analysis. </p> </section> <section id="CD012332-sec-0077"> <h4 class="title">Participants experiencing any adverse event</h4> <p>This outcome was reported by four studies (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). </p> <p> <ul id="CD012332-list-0010"> <li> <p>The proportion of participants with at least one adverse event with NSAID was 31% (35/114); range 11% to 44%. </p> </li> <li> <p>The proportion of participants with at least one adverse event with placebo was 22% (26/116); range 11% to 41%. </p> </li> <li> <p>The RD for NSAID compared with placebo was 0.08 (95% CI ‐0.03 to 0.19) (<a href="./references#CD012332-fig-0006" title="">Analysis 1.4</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome by three levels to very low quality because of the small size of studies and pooled data set, and because there were only 61 actual events in the analysis. </p> </section> <section id="CD012332-sec-0078"> <h4 class="title">Withdrawals due to lack of efficacy and for any cause</h4> <p>Lack of efficacy withdrawal was reported by treatment group in only two studies (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>). In the former there were no lack of efficacy withdrawals in either group, and in the latter there were 3/41 with tenoxicam and 3/41 with placebo. </p> <p>Withdrawal for any cause was reported by treatment group in three studies (<a href="./references#CD012332-bbs2-0003" title="MahagnaH , AmitalD , AmitalH . A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. International Journal of Clinical Practice2016;70(2):163‐70. [CTG: NCT00755521; DOI: 10.1111/ijcp.12760] ">Mahagna 2016</a>; <a href="./references#CD012332-bbs2-0004" title="Quijada‐CarreraJ , Valenzuela‐CastañoA , Povedano‐GómezJ , Fernández‐RodriguezA , Hernánz‐MedianoW , Gutierrez‐RubioA , et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double‐blind, placebo‐controlled trial. Pain1996;65(2):221‐5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD012332-bbs2-0006" title="YunusMB , MasiAT , AldagJC . Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. Journal of Rheumatology1989;16(4):527‐32. ">Yunus 1989</a>). </p> <p> <ul id="CD012332-list-0011"> <li> <p>The proportion of participants withdrawing for any cause with NSAID was 23% (22/95); range 9% to 41%. </p> </li> <li> <p>The proportion of participants withdrawing for any cause with placebo was 20% (19/97); range 6% to 37%. </p> </li> <li> <p>The RD for NSAID compared with placebo was 0.03 (95% CI ‐0.07 to 0.14) (<a href="./references#CD012332-fig-0007" title="">Analysis 1.5</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome by three levels to very low quality because of the small size of studies and pooled data set, and because there were only 41 actual events in the analysis. There was also inconsistency between studies, with the bulk of the withdrawals in one of the three studies (32/41 withdrawals), despite there being no statistical heterogeneity (I<sup>2</sup> = 0). </p> </section> <section id="CD012332-sec-0079"> <h4 class="title">Participant‐reported improvement of health‐related quality of life</h4> <p>Although most of the studies had some measures of health‐related quality of life, fibromyalgia impact, or other outcomes, none reported the outcomes beyond saying that there was no or little difference between the treatment groups. </p> </section> <section id="CD012332-sec-0080"> <h4 class="title">Specific adverse events</h4> <p>These were not reported in sufficient detail or consistency to be amenable to analysis.</p> </section> <section id="CD012332-sec-0081"> <h4 class="title">Outcomes (expected to be continuous variables)</h4> <p>Outcomes (expected to be continuous variables) relating to sleep problems, depression, anxiety, and fatigue were not reported. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012332-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012332-sec-0082"></div> <section id="CD012332-sec-0083"> <h3 class="title" id="CD012332-sec-0083">Summary of main results</h3> <p>Participants in these studies typically had moderate or severe pain of fibromyalgia, often long‐lasting, and with an initial average pain score of about 7/10 at the start of the studies. A pain score of 7/10 would be regarded as severe pain. The primary pain outcomes of this review were 'substantial' pain relief, ideally a reduction in pain intensity by 50% or more, and 'moderate' pain relief, a reduction by 30% or more, which was sustained over the duration of the trial, typically three months. These outcomes are judged as desirable by people with pain (<a href="./references#CD012332-bbs2-0077" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> <p>Some, but not all, of the six small studies reported these pain outcomes or something very similar to them. Although the number of participants providing information for these and other outcomes barely amounted to 200 in total, we performed analyses for a number of the outcomes. NSAIDs proved no better than placebo in producing pain relief. While there was no difference in a number of adverse event measures and withdrawals, the small amount of information available in these studies was quite inadequate to examine rare but serious adverse events of NSAIDs. </p> <p>The bottom line is that there is no evidence that NSAIDs are beneficial for pain reduction or any other outcome in fibromyalgia, despite being used commonly to treat the condition (<a href="./references#CD012332-bbs2-0042" title="HäuserW , JungE , Erbslöh‐MöllerB , GesmannM , Kühn‐BeckerH , PetermannF , et al. The German fibromyalgia consumer reports ‐ a cross‐sectional survey. BMC Musculoskeletal Disorders2012;13:74. [DOI: 10.1186/1471‐2474‐13‐74] ">Häuser 2012</a>; <a href="./references#CD012332-bbs2-0095" title="ShaverJL , WilburJ , LeeH , RobinsonFP , WangE . Self‐reported medication and herb/supplement use by women with and without fibromyalgia. Journal of Womens Health2009;18(5):709‐16. [DOI: 10.1089/jwh.2008.1194] ">Shaver 2009</a>; <a href="./references#CD012332-bbs2-0111" title="WolfeF , WalittBT , KatzRS , LeeYC , MichaudKD , HäuserW . Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain2014;17(4):581‐6. [DOI: 10.1002/j.1532‐2149.2012.00234.x] ">Wolfe 2014b</a>). </p> <p>Small studies of modest quality tend to overestimate effects of treatment ((<a href="./references#CD012332-bbs2-0021" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;f2304:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD012332-bbs2-0022" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312(6):623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012332-bbs2-0065" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012332-bbs2-0085" title="NüeschE , HäuserW , BernardyK , BarthJ , JüniP . Comparative efficacy of pharmacological and non‐pharmacological interventions in fibromyalgia syndrome: network meta‐analysis. Annals of the Rheumatic Diseases2013;72(6):955‐62. [DOI: 10.1136/annrheumdis‐2011‐201249] ">Nüesch 2013</a>), and to have a positive bias towards the experimental intervention. No such benefits were seen. Consequently, NSAIDs cannot be regarded as useful for treating fibromyalgia. </p> </section> <section id="CD012332-sec-0084"> <h3 class="title" id="CD012332-sec-0084">Overall completeness and applicability of evidence</h3> <p>The demographic data of the study participants were typical of people with fibromyalgia, being mainly women in their 50s, with a reliable diagnosis of fibromyalgia, with moderate or severe pain and functional disability. However, participants with inflammatory rheumatic diseases and mental disorders, which are frequently associated with fibromyalgia, were excluded by the studies. The study results cannot therefore be applied to many people with fibromyalgia in routine clinical care. </p> </section> <section id="CD012332-sec-0085"> <h3 class="title" id="CD012332-sec-0085">Quality of the evidence</h3> <p>All of the studies in the review were described as randomised and double‐blind, had Oxford Quality Scores of 3/5 or above, and were at high risk of bias only for their small size. A number of quality measures were inadequately described, however, and some risk of bias cannot be excluded. Studies generally lasted for four weeks or longer, and while the longest duration was eight weeks, the studies would all be considered relatively short term for a chronic condition. Diagnostic criteria for inclusion were reasonable, using appropriate definitions and duration of pain. Participants had to have had initial pain of at least moderate intensity, meaning that studies would be sensitive enough to measure any analgesic effect. </p> <p>Sample sizes were small, increasing the risk of random chance effects and small study bias. About half of the studies reported clinically useful outcomes, so that pooled analyses were typically on only about 200 participants, where chance effects are possible (<a href="./references#CD012332-bbs2-0065" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). In view of the small sample sizes, as well as uncertainties for other possible risks of bias, we chose to downgrade the quality of the evidence by three levels, to very low quality. Very low quality means that this research does not provide a reliable indication of the likely effect. The likelihood that the effect could be substantially different is very high. </p> </section> <section id="CD012332-sec-0086"> <h3 class="title" id="CD012332-sec-0086">Potential biases in the review process</h3> <p>We know of no potential biases in the review process. We had planned to calculate the number of participants who would need to be in trials with zero effect (risk ratio of 1.0) needed for the point estimate of the NNT to increase beyond a clinically useful level (<a href="./references#CD012332-bbs2-0066" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>), but this method is not applicable with low effect sizes. </p> </section> <section id="CD012332-sec-0087"> <h3 class="title" id="CD012332-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>Previous systematic reviews have examined the efficacy of NSAIDs in fibromyalgia. Four of the six studies in this review were included in a previous broad review and guidance, with a negative recommendation (<a href="./references#CD012332-bbs2-0097" title="SommerC , HäuserW , AltenR , PetzkeF , SpäthM , TölleT , et al. Drug therapy of fibromyalgia syndrome. Systematic review, meta‐analysis and guideline [Arbeitsgemeinschaft der wissenschaftlichen medizinischen fachgesellschaften]. Schmerz2012;26(3):297‐310. [DOI: 10.1007/s00482‐012‐1172‐2] ">Sommer 2012b</a>). Other reviews have identified a general lack of evidence (<a href="./references#CD012332-bbs2-0046" title="HäuserW , WalittB , FitzcharlesMA , SommerC . Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research and Therapy2014;16(1):201. [DOI: 10.1186/ar4441] ">Häuser 2014b</a>), or have not addressed NSAIDs (<a href="./references#CD012332-bbs2-0085" title="NüeschE , HäuserW , BernardyK , BarthJ , JüniP . Comparative efficacy of pharmacological and non‐pharmacological interventions in fibromyalgia syndrome: network meta‐analysis. Annals of the Rheumatic Diseases2013;72(6):955‐62. [DOI: 10.1136/annrheumdis‐2011‐201249] ">Nüesch 2013</a>). NSAIDs are either ignored or not recommended by guidelines for treating fibromyalgia (<a href="./references#CD012332-bbs2-0042" title="HäuserW , JungE , Erbslöh‐MöllerB , GesmannM , Kühn‐BeckerH , PetermannF , et al. The German fibromyalgia consumer reports ‐ a cross‐sectional survey. BMC Musculoskeletal Disorders2012;13:74. [DOI: 10.1186/1471‐2474‐13‐74] ">Häuser 2012</a>; <a href="./references#CD012332-bbs2-0058" title="MacfarlaneGJ , KronischC , DeanLE , AtzeniF , HäuserW , FlußE , et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases2017;76(2):318‐28. [DOI: 10.1136/annrheumdis‐2016‐209724] ">Macfarlane 2017</a>; <a href="./references#CD012332-bbs2-0097" title="SommerC , HäuserW , AltenR , PetzkeF , SpäthM , TölleT , et al. Drug therapy of fibromyalgia syndrome. Systematic review, meta‐analysis and guideline [Arbeitsgemeinschaft der wissenschaftlichen medizinischen fachgesellschaften]. Schmerz2012;26(3):297‐310. [DOI: 10.1007/s00482‐012‐1172‐2] ">Sommer 2012b</a>). </p> <p>A separate Cochrane Review is investigating the use of combination pharmacotherapy in fibromyalgia (<a href="./references#CD012332-bbs2-0032" title="GilronI , ShumB , MooreRA , WiffenPJ . Combination pharmacotherapy for the treatment of fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010585] ">Gilron 2013</a>). It is likely to support a negative view of NSAIDs in fibromyalgia, based on results of trials included in this review (<a href="./references#CD012332-bbs2-0001" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371‐7. [DOI: 10.1002/art.1780291110] ">Goldenberg 1986</a>; <a href="./references#CD012332-bbs2-0005" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1991;34(5):552‐60. [DOI: 10.1002/art.1780340507] ">Russell 1991</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012332-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012332-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAID versus placebo, Outcome 1 Substantial pain relief." data-id="CD012332-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 NSAID versus placebo, Outcome 1 Substantial pain relief.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAID versus placebo, Outcome 2 Moderate pain relief." data-id="CD012332-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 NSAID versus placebo, Outcome 2 Moderate pain relief.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAID versus placebo, Outcome 3 Adverse event withdrawal." data-id="CD012332-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 NSAID versus placebo, Outcome 3 Adverse event withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAID versus placebo, Outcome 4 Participants with at least one adverse event." data-id="CD012332-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 NSAID versus placebo, Outcome 4 Participants with at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012332-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/urn:x-wiley:14651858:media:CD012332:CD012332-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_t/tCD012332-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NSAID versus placebo, Outcome 5 All‐cause withdrawal." data-id="CD012332-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 NSAID versus placebo, Outcome 5 All‐cause withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/media/CDSR/CD012332/image_n/nCD012332-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012332-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAID compared with placebo for fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAID compared with placebo for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with fibromyalgia</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: any NSAID</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> <p><b>(at trial end)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> NSAID</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substantial pain relief:</p> <p>at least 50% reduction in pain, or</p> <p>PGIC much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.07 (95% CI ‐0.18 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>146 participants</p> <p>21 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain relief:</p> <p>at least 30% reduction in pain, or</p> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.04 (95% CI ‐0.16 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>192 participants</p> <p>46 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event withdrawal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.04 (95% CI ‐0.02 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>230 participants</p> <p>8 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.08 (95% CI ‐0.03 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>230 participants</p> <p>61 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause withdrawal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.03 (‐0.07 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies</p> <p>192 participants</p> <p>41 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded three levels due to small number of studies, participants, and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012332-bbs2-0026" title="EffectivePractice , Organisation of Care(EPOC) . EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services2015; Vol. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>a</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>a</sup> is very high. </p> <p><sup>a</sup>Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NSAID compared with placebo for fibromyalgia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/full#CD012332-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012332-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAID versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Substantial pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.18, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Moderate pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.16, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse event withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.02, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants with at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.03, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAID versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012332.pub2/references#CD012332-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012332.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012332-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012332-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012332-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012332-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012332-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012332\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012332\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012332\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012332\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012332.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012332.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012332.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012332.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012332.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729091553"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012332.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729091557"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012332.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed4701cdff56f',t:'MTc0MDcyOTA5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 